Article

1 Iconography
1 Complement
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Joint Bone Spine
Sous presse. Epreuves corrigées par l'auteur. Disponible en ligne depuis le vendredi 13 mars 2020
Doi : 10.1016/j.jbspin.2020.02.003
Received : 29 September 2019 ;  accepted : 12 February 2020
Squamous cell carcinoma antigen-IgM (SCCA-IgM) is associated with interstitial lung disease in systemic sclerosis
 

Elisabetta Zanatta a, 1, Andrea Martini b, 1, Elena Scarpieri a, Alessandra Biasiolo b, Augusta Ortolan a, Francesco Benvenuti a, Franco Cozzi a, Patrizia Pontisso b, Andrea Doria a,
a Division of Rheumatology, Department of Medicine-DIMED, University of Padova,, 35128 Padova, Italy 
b Unit of Internal Medicine and Hepatology (UIMH), Department of Medicine-DIMED, University of Padova, 35128 Padova, Italy 

Corresponding author.
Highlights

Squamous Cell Carcinoma Antigen (SCCA-IgM) is associated with interstitial lung disease (ILD) in systemic sclerosis (SSc).
SCCA-IgM seems able to improve the diagnostic performance of total lung capacity (TLC), identifying patients with a very low risk of SSc-ILD.
SCCA-IgM could be particularly useful in the early assessment of SSc-ILD.

The full text of this article is available in PDF format.
Abstract
Objective

Interstitial lung disease (ILD) is the major determinant of prognosis in patients with systemic sclerosis (SSc). Squamous Cell Carcinoma Antigen (SCCA1) is a serin protease inhibitor which plays a pivotal role in inflammation and fibrosis. SCCA1 is overexpressed in pulmonary tissue of patients with idiopathic pulmonary fibrosis and can be detectable in serum as circulating immune complex bound to IgM (SCCA-IgM). We aimed to investigate the association between SCCA-IgM and clinical features of patients with SSc.

Methods

Ninety-seven patients with SSc (ACR/EULAR criteria) were consecutively enrolled in the study. Clinical and serological variables and organ involvement were recorded. Pulmonary involvement was investigated by high-resolution CT (HRCT) and respiratory function tests. SCCA-IgM serum levels were measured by a validated ELISA assay (Hepa-IC, Xeptagen, Venice, Italy). We set the cut-off value for serum levels of SCCA-IgM >200 AU/ml, calculated as mean+3 standard deviations in 100 healthy subjects.

Results

Forty-one (42.3%) patients were affected with ILD. SCCA-IgM values were significantly higher in patients with ILD than in those without: 218 (80-402) vs. 87.5 (59-150) AU/mL, P= 0.003. Patients with positive SCCA-IgM had more frequently ILD (69.7% vs. 28.1%, P0.0001) and a lower total lung capacity (TLC) (P= 0.024) compared with negative ones. No differences were found in any other clinical and serological features. At multivariate analysis, SCCA-IgM was found to be associated with ILD diagnosis (OR 10.6, IC 2.9-38.4, P= 0.001).

Conclusion

SCCA-IgM is associated with interstitial lung disease in scleroderma patients and might be used in the assessment of SSc-ILD.

The full text of this article is available in PDF format.

Keywords : Systemic sclerosis, Interstitial lung disease, SCCA-IgM, Serpinb3


1  These two authors contributed equally to the article.


© 2020  Société française de rhumatologie@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline